MSD’s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers ...

Injectable HIV therapy offers hope for those who struggle with daily pills—providing a powerful, long-lasting alternative to ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers ...

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

Phase 1 Data Indicate Potential for Use of Once-Yearly Lenacapavir for HIV Prevention, with Plans to Launch a Phase 3 Trial in 2H 2025 – ...

The new study, published in The Lancet, is the first to evaluate a once-yearly injection of an HIV pre-exposure prophylaxis ...

The global HIV drugs industry was valued at USD 28.6 billion in 2023 and is projected to grow at a CAGR of 4.7% from 2024 to ...

North America was the major shareholder in 2022. However, Asia-Pacific is expected to witness the highest CAGR during the forecast period. PO ...